Clinical Scorecard: Pilot Evaluation of a Standardized Three-Dose Intravenous Tranexamic Acid Regimen for Bariatric Surgery

At a Glance

Key Highlights

• The study evaluated feasibility of a standardized three-dose intravenous TXA regimen; clinical outcomes were exploratory.
• The regimen was 1 g intravenously at anesthesia induction, on the evening of surgery, and the following morning.
• Of 1,122 screened patients, 1,077 were included; 549 were assigned to TXA periods and 528 to non-TXA periods on an intention-to-treat basis.
• TXA and non-TXA periods used the same standardized thromboprophylaxis protocol.
• Exploratory outcomes included clinically significant bleeding, operative time, length of stay, and thromboembolic events through postoperative day 30.

Guideline-Based Recommendations

Diagnosis

• The study defined clinically significant bleeding by events including transfusion, operative reintervention, endoscopy, an unplanned bleeding-related emergency department encounter or readmission, hemodynamic instability, or shock.
• Suspected VTE was recorded as an event only after objective confirmation.

Management

• The evaluated TXA regimen consisted of three intravenous 1-g doses: at anesthesia induction, on the evening of surgery, and the following morning.
• Standardized thromboprophylaxis began with subcutaneous unfractionated heparin at anesthesia induction and continued every 8 hours during hospitalization.
• After discharge, thromboprophylaxis followed the institutional protocol of enoxaparin 40 mg subcutaneously twice daily for 14 days.

Monitoring & Follow-up

• Feasibility assessment included recruitment, adherence to allocated treatment and the three-dose schedule, and completeness of follow-up through 30 days.
• Postoperative outcomes were determined using the electronic medical record, scheduled assessment, and telephone contact when applicable.
• Symptomatic patients suspected of VTE received focused diagnostic testing.

Risks

• The article identifies postoperative bleeding and VTE as important perioperative risks in bariatric surgery.
• The study rationale notes the need to balance bleeding risk against VTE risk when evaluating perioperative TXA alongside anticoagulation.
• The supplied article text does not report study outcome results or establish TXA efficacy or safety.

Patient & Prescribing Data

Adults undergoing sleeve gastrectomy, Roux-en-Y gastric bypass, or revisional surgery at a single academic institution; 1,077 patients were included after excluding those under 18 or with absolute TXA contraindications.

The evaluated protocol used three intravenous 1-g TXA doses, each diluted in 100 mL normal saline, at anesthesia induction, on the evening of surgery, and the following morning. The comparison periods used the same perioperative management and thromboprophylaxis without TXA.

Clinical Best Practices

• The study used a standardized TXA dosing schedule and standardized thromboprophylaxis across treatment periods.
• Assess protocol adherence by documenting whether the allocated intervention and, for TXA recipients, all three doses were administered.
• Assess postoperative bleeding and thromboembolic events through 30 days, using objective confirmation for VTE.
• Interpret the investigation as a feasibility pilot with exploratory clinical endpoints; the sample size was not calculated to assess efficacy.

Related Resources & Content